View our webinar on Dual CRISPRi and CRISPRa screening which can power up your drug discovery and development programs, improving your rate of target discovery:
Ben joined Horizon in 2013 to expand and develop Horizon’s functional genomic screening capability and to lead a major research alliance in synthetic lethal target discovery. Ben now is Horizon’s functional genomic screening platform including the CRISPR screening service. Prior to working at Horizon, Ben completed his PhD at the Univ. of Manchester and trained as a post-doctoral scientist at the Univ. of Cambridge studying reverse chemical genetic screening in the unfolded protein response.